Trilac

Triamcinolone acetonide

IA: Alleviating joint pain, swelling & stiffness associated w/ RA & OA; bursitis, epicondylitis & tenosynovitis. Intradermal (ID): Lichen simplex chronicus (neuro-dermatitis), granuloma annulare, lichen planus, keloids, alopecia areata & hypertrophic scars.

Adult IA administration & inj into tendon sheaths & bursae: 2.5-5 mg (0.25-0.5 mL) for smaller joins; 5-15 mg (0.5-1.5 mL) for larger joints. ID: 2-3 mg (0.2-0.3 mL), depending on the size of the lesion. Not >5 mg (0.5 mL) should be inj at any site or not exceed 30 mg (3 mL) at several sites. May be repeated at 1-2 wk intervals.

Hypersensitivity. Systemic infections. Not for IV, intrathecal, epidural or intraocular inj.

Anaphylactic shock, including death. Do not inj into unstable joints. Severe joint destruction w/ bone necrosis in prolonged therapy. Active infection (in or near joints). Development of adrenal cortical atrophy during prolonged therapy. Increased susceptibility to infections. Chickenpox & measles. Possible psychiatric disturbances. Patients w/ existing or previous history of severe affective disorders. Recent intestinal anastomoses, diverticulitis, thrombophlebitis, exanthematous disease, chronic nephritis, or renal insufficiency, metastatic carcinoma, osteoporosis (post-menopausal females are particularly at risk); in patients w/ an active peptic ulcer (or a history of peptic ulcer). Myasthenia gravis. Latent or healed TB; in the presence of local or systemic viral infection, systemic fungal infections or in active infections not controlled by antibiotics. In acute psychoses; in acute glomerulonephritis. HTN; CHF; glaucoma (or a family history of glaucoma), previous steroid myopathy or epilepsy. Liver failure. Concomitant use w/ acetonide & ritonavir. Hypothyroidism or cirrhosis; hyperthyroid. Latent DM. Menstrual irregularities & vag bleeding in postmenopausal women. Pregnancy & Lactation. Childn <3 yr.

IA: Post-inj flare, transient pain, irritation at the inj site, sterile abscess formation, hyperpigmentation & hypopigmentation, charcot-like arthropathy, brief increase in joint discomfort. ID: Transient local discomfort, sterile abscesses, hyper-/hypopigmentation & SC/cutaneous atrophy. Cushingoid.

Hypokalemia w/ amphotericin B inj & K-depleting agents. Antagonism w/ anticholinesterases; antihypertensives & diuretics. May potentiate or decrease action of anticoagulants. May increase blood glucose. Enhanced hypokalaemic effects of diuretics including acetazolamide. Increased toxicity of cyclosporine. May enhance digitalis toxicity. May increase t_½ & conc & decrease clearance w/ estrogens including OCs. May increase metabolic clearance w/ hepatic enzyme inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin). May inhibit growth-promoting effect of human growth hormone (eg, somatrem). Increased adverse effects w/ strong CYP3A4 inhibitors (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin. May decrease or enhance neuromuscular blocking action of nondepolarising muscle relaxants. May increase incidence &/or severity of GI bleeding & ulceration w/ NSAIDs. May reduce serum salicylate levels. Decreased metabolic clearance w/ thyroid drugs. Neurological complications & lack of antibody response w/ vaccines.

Corticosteroid Hormones

H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.

Rx